Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Lung Neoplasms × apatinib × Clear all

Status

Sponsor Class

Study Type

Interventional 6 Observational 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety 1 Lung Neoplasms 1 Liver Neoplasms 1 Glioma 1 Glioblastoma 1 Carcinoma, Hepatocellular 1 Breast Cancer Organoids 1 Advanced Gastric Cancer 1

Interventions

Surveys and Questionnaires 19 Blood Specimen Collection 18 Gene Expression Profiling 12 Radiotherapy 11 Magnetic Resonance Spectroscopy 9 Surgical Procedures, Operative 8 Specimen Handling 8 Immunohistochemistry 8 Polymerase Chain Reaction 7 Drug Therapy 7 pembrolizumab 6 Observation 6 Amplified Fragment Length Polymorphism Analysis 6 Tomography, X-Ray Computed 5 Reverse Transcriptase Polymerase Chain Reaction 5 Psychiatric Rehabilitation 5 Liquid Biopsy 5 Interviews as Topic 5 Carboplatin 5 Bronchoscopy 5 Thoracic Surgery, Video-Assisted 4 Therapeutics 4 Paclitaxel 4 Microarray Analysis 4 Ipilimumab 4 Biopsy 4 Bevacizumab 4 osimertinib 3 durvalumab 3 atezolizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03376191 2017-12-18

Apatinib in Advanced Non-squamous，NSCLC

Peking University Cancer Hospital & Institute

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡